Rational Engraftment of Quaternary-Interactive Acidic Loops for Anti-HIV-1 Antibody Improvement

Monoclonal antibodies represent one of the most important recent innovations in the fight against infectious diseases. Although potent antibodies can be cloned from infected individuals, various strategies can be employed to improve their activity or pharmacological features. ABSTRACT Broadly neutralizing antibodies (bNAbs) are the focus of increasing interest for human immunodeficiency virus type 1 (HIV-1) prevention and treatment. Although several bNAbs are already under clinical evaluation, the development of antibodies with even greater potency and breadth remains a priority. Recently, we reported a novel strategy for improving bNAbs against the CD4-binding site (CD4bs) of gp120 by engraftment of the elongated framework region 3 (FR3) from VRC03, which confers the ability to establish quaternary interactions with a second gp120 protomer. Here, we applied this strategy to a new series of anti-CD4bs bNAbs (N49 lineage) that already possess high potency and breadth. The resultant chimeric antibodies bound the HIV-1 envelope (Env) trimer with a higher affinity than their parental forms. Likewise, their neutralizing capacity against a global panel of HIV-1 Envs was also increased. The introduction of additional modifications further enhanced the neutralization potency. We also tried engrafting the elongated CDR1 of the heavy chain from bNAb 1-18, another highly potent quaternary-binding antibody, onto several VRC01-class bNAbs, but none of them was improved. These findings point to the highly selective requirements for the establishment of quaternary contact with the HIV-1 Env trimer. The improved anti-CD4bs antibodies reported here may provide a helpful complement to current antibody-based protocols for the therapy and prevention of HIV-1 infection. IMPORTANCE Monoclonal antibodies represent one of the most important recent innovations in the fight against infectious diseases. Although potent antibodies can be cloned from infected individuals, various strategies can be employed to improve their activity or pharmacological features. Here, we improved a lineage of very potent antibodies that target the receptor-binding site of HIV-1 by engineering chimeric molecules containing a fragment from a different monoclonal antibody. These engineered antibodies are promising candidates for development of therapeutic or preventive approaches against HIV/AIDS.

[1]  Mitchell Ho,et al.  COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19 , 2020, Antibody therapeutics.

[2]  N. Garrett,et al.  Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review , 2020, The Journal of infectious diseases.

[3]  B. Korber,et al.  Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. , 2020, Annual review of immunology.

[4]  L. Corey,et al.  Broadly Neutralizing Antibodies for HIV Prevention. , 2020, Annual review of medicine.

[5]  J. Bloom,et al.  Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody , 2020, Cell.

[6]  T. Chun,et al.  Durable Control of HIV Infection in the Absence of Antiretroviral Therapy: Opportunities and Obstacles. , 2019, JAMA.

[7]  J. Mascola,et al.  Improvement of antibody functionality by structure-guided paratope engraftment , 2019, Nature Communications.

[8]  F. Klein,et al.  Antibody-mediated prevention and treatment of HIV-1 infection , 2018, Retrovirology.

[9]  J. Tartaglia,et al.  Faculty Opinions recommendation of Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[10]  G. Cavet,et al.  Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses , 2018, Cell.

[11]  Haniye Sadat Sajadi,et al.  Spending on health and HIV/AIDS: domestic health spending and development assistance in 188 countries, 1995–2015 , 2018, The Lancet.

[12]  J. Mascola,et al.  Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1 , 2018, bioRxiv.

[13]  J. Mascola,et al.  Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody , 2018, Cell reports.

[14]  G. Chuang,et al.  Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer , 2017, Nature Structural &Molecular Biology.

[15]  Tongqing Zhou,et al.  Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. , 2016, Immunity.

[16]  Young Do Kwon,et al.  Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G , 2016, Cell.

[17]  Cinque S. Soto,et al.  Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors , 2015, Cell.

[18]  Young Do Kwon,et al.  Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo , 2014, Journal of Virology.

[19]  J. Mascola,et al.  Enhanced neonatal Fc receptor function improves protection against primate SHIV infection , 2014, Nature.

[20]  Ron Diskin,et al.  Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design , 2011, Science.

[21]  Ron Diskin,et al.  Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.